WuXi Biologics (Cayman) Inc. (2269.HK)
HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
113.300+0.200 (+0.18%)
At close: 4:08PM HKT
Currency in HKD
Valuation measures
| Market cap (intra-day) 5 | 486.96B |
| Enterprise value 3 | 475.67B |
| Trailing P/E | 148.64 |
| Forward P/E 1 | 100.00 |
| PEG ratio (5-yr expected) 1 | 1.96 |
| Price/sales (ttm) | 51.13 |
| Price/book (mrq) | 12.14 |
| Enterprise value/revenue 3 | 58.91 |
| Enterprise value/EBITDA 7 | 141.57 |
Trading information
Stock price history
| Beta (5Y monthly) | 1.07 |
| 52-week change 3 | 55.49% |
| S&P500 52-week change 3 | 33.64% |
| 52-week high 3 | 148.000 |
| 52-week low 3 | 70.133 |
| 50-day moving average 3 | 117.709 |
| 200-day moving average 3 | 119.148 |
Share statistics
| Avg vol (3-month) 3 | 17.65M |
| Avg vol (10-day) 3 | 10.92M |
| Shares outstanding 5 | 4.24B |
| Implied shares outstanding 6 | N/A |
| Float 8 | 3.58B |
| % held by insiders 1 | 15.65% |
| % held by institutions 1 | 46.28% |
| Shares short 4 | N/A |
| Short ratio 4 | N/A |
| Short % of float 4 | N/A |
| Short % of shares outstanding 4 | N/A |
| Shares short (prior month ) 4 | N/A |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | N/A |
| Trailing annual dividend yield 3 | N/A |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 3:1 |
| Last split date 3 | 16 Nov 2020 |
Financial highlights
Currency in CNY.Fiscal year
| Fiscal year ends | 31 Dec 2020 |
| Most-recent quarter (mrq) | 30 Jun 2021 |
Profitability
| Profit margin | 34.61% |
| Operating margin (ttm) | 34.53% |
Management effectiveness
| Return on assets (ttm) | 5.42% |
| Return on equity (ttm) | 12.01% |
Income statement
| Revenue (ttm) | 8.08B |
| Revenue per share (ttm) | 1.97 |
| Quarterly revenue growth (yoy) | 126.70% |
| Gross profit (ttm) | 2.53B |
| EBITDA | 3.16B |
| Net income avi to common (ttm) | 2.79B |
| Diluted EPS (ttm) | N/A |
| Quarterly earnings growth (yoy) | 150.30% |
Balance sheet
| Total cash (mrq) | 13.94B |
| Total cash per share (mrq) | 3.29 |
| Total debt (mrq) | 4.6B |
| Total debt/equity (mrq) | 13.69 |
| Current ratio (mrq) | 4.04 |
| Book value per share (mrq) | 7.84 |
Cash flow statement
| Operating cash flow (ttm) | 2.25B |
| Levered free cash flow (ttm) | -6.86B |
© 2021 Verizon Media. All rights reserved.
